Brainomix Announces New Partnership with Boehringer Ingelheim to Develop AI-Powered Radiomics Software for Automated Solid Tumor Cancer Assessment

0

The collaboration will focus on the development of AI tools to improve the accuracy and standardization of tumor measurement in lung cancer trials

OXFORD, England, February 1, 2022 /PRNewswire/ — Brainomix today announced a new partnership with Boehringer Ingelheim to improve the accuracy and standardization of tumor measurement in clinical trials through the continued development of fully automated AI software to segmentation and characterization of tumor lesions. Through this partnership, Brainomix will leverage its existing capabilities in AI-based medical software development, supported by Boehringer Ingelheim’s expertise in clinical development and translation of technological innovations into impactful applications.

Brainomix, a Oxfordspecializing in cutting-edge AI-powered medical technology solutions, can leverage quantitative imaging to identify and monitor patients during and during treatment. The company has demonstrated significant success after developing and commercializing the world’s first fully automated AI solution for stroke assessment (e-Stroke), and this new partnership with Boehringer Ingelheim marks the start of the expansion of Brainomix in applications beyond the brain.

Unbiased and comprehensive quantitative image analysis is an essential method of assessing treatment response, but current methods rely on subjective, human interpretation. Determination of tumor response is based on the Response Evaluation Criteria in Solid Tumors (RECIST). The US Food and Drug Administration (FDA) found that there is a 30% discrepancy between the original and confirmatory independent readings. Additionally, modern digital data files (i.e. those generated by CT) contain richer information than that captured by RECIST. AI-based methods will be used to develop machine learning algorithms that could detect, measure and calculate total tumor burden to enable quantitative, unbiased, comprehensive and faster assessment of the disease and its changes.

“We are very pleased to announce this partnership with Boehringer Ingelheim, a leading research-driven biopharmaceutical company. By leveraging our existing technology platform and our expertise in developing cutting-edge AI solutions, we can together create a robust radiomics solution for oncology that will improve both the evaluation and translation of drugs in development. clinic,” said Eric Greveson, Chief Technology Officer at Brainomix.

Teacher. Florian GantnerHead of Translational Medicine and Clinical Pharmacology at Boehringer Ingelheim, said, “The partnership has the potential to help us confidently interpret patient responses to treatment during our clinical trials. Innovation at Boehringer Ingelheim is, and always has been, about patients. Image analysis technology based on Brainomix AI can allow us to accelerate the development of much-needed lung cancer treatments. »

This partnership will build on Brainomix’s existing offering to pharmaceutical and medical partners, where the development and deployment of AI-powered biomarkers drive value during clinical development and can drive wider adoption of existing therapies and news.

About Brainomix

Brainomix is ​​a Oxfordspecializing in creating AI-based software solutions to enable precision medicine to make better treatment decisions for stroke and certain lung conditions. Since its launch as a spin-out of University of Oxford, he has developed award-winning AI-powered imaging biomarkers and software solutions, helping physicians around the world make better, life-saving decisions. Its e-Stroke platform offers clinicians the most comprehensive imaging solution for stroke, helping to accelerate treatment times and improve patients’ functional independence. To learn more about Brainomix and its technology, visit www.brainomix.com and follow TwitterLinkedIn and Facebook.

Logo – https://mma.prnewswire.com/media/1311028/Brainomix_Logo.jpg

Share.

Comments are closed.